The global ADME toxicology testing market size is expected to generate revenue of USD 10.25 billion by 2025, exhibiting a CAGR of 11.4% during the forecast period. Factors such as increased need to check late-stage drug failures with adoption of more appropriate toxicity testing methods by pharmaceutical companies is expected to aid revenue generation for the market.
Absorption, distribution, metabolism,
and excretion (ADME) toxicology testing is used to test toxic reactions caused
by molecules in clinical trials on factors and systemic reactions such as
chemical, pharmaceutical, and genetic. These toxicology testing procedures help
in effective drug development, which limits or prevents toxic reactions to the
body when administered. Toxicity levels are decided on the results of a series
of tests conducted in near natural conditions, which represent almost real-time
reactions between the drug and host.
As of 2017, approximately 43.0% of ADME
toxicology testing areas carried out are based on cell culture tech. Cell
culture technology is adopted widely owing to advantages such as near natural
conditions and accurate results obtained at a cellular level.
These assays are conducted for several
types of toxic reactions or systems where toxic reactions might take place.
Some of the toxicity tests are systemic toxicity, renal toxicity,
hepatotoxicity, neurotoxicity, and other toxicities that might result in a
living tissue. Advancements in testing methods are underway and this trend is
likely to be picked up by many companies developing drug molecules. This will
speed up the drug discovery process and boost market growth.
Free
Exclusive Sample of this report @ https://www.radiantinsights.com/research/adme-toxicology-testing-market/request-sample
Further
key findings from the report suggest:
• The market is driven by increasing
ratio of late-stage drug failures, resulting in loss of valuable time and
investment for drug development. Growth and increasing adoption of OMICS
technology is also expected to boost revenue generation in the coming years
• North America is the largest market
for ADME toxicology testing owing to presence of large number of pharmaceutical
companies competing for commercial launch of novel molecules
• Developing regions of Asia Pacific and
Latin America are set to grow considerably as many multinational and local
players are striving to enter the market. They are also looking improve their
hold in markets that present innovation and growth opportunities
• Some of the key players in this market
are Accelrys Inc.; Agilent Technologies, Inc.; Albany Molecular Research Inc.;
Beckman Coulter Inc.; Catalent Inc.; Charles River Laboratories International
Inc.; AbbVie; Actelion Pharmaceuticals; Amgen; Biocon; BioMarin; Boehringer
Ingelheim; Bristol-Myers Squibb; Cipla; and CymaBay Therapeutics.
Browse Full Report With TOC @ https://www.radiantinsights.com/research/adme-toxicology-testing-market
About
Radiant Insights
Radiant Insights is a platform for
companies looking to meet their market research and business intelligence
requirements. We assist and facilitate organizations and individuals procure
market research reports, helping them in the decision making process. We have a
comprehensive collection of reports, covering over 40 key industries and a host
of micro markets. In addition to over extensive database of reports, our
experienced research coordinators also offer a host of ancillary services such
as, research partnerships/ tie-ups and customized research solutions.
Media
Contact:
Michelle Thoras
201 Spear Street 1100,
Suite 3036, San Francisco,
CA 94105, United States
Tel: 1-415-349-0054
Toll Free: 1-888-928-9744
Mail: sales@radiantinsights.com
No comments:
Post a Comment